Pharmaceutical News

RSS

Everolimus therapy might treat Myc-driven lymphoma

Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

15 Dec 2012

Novartis receives FDA approval for Signifor injection to treat Cushing's disease

The U.S. Food and Drug Administration today approved Signifor (pasireotide diaspartate) injection for the treatment of Cushing's disease patients who cannot be helped through surgery.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Study suggests that existing HIV drug could be a potential therapy for Staph infections

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year.

15 Dec 2012

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

14 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Paroxetine could treat vascular complications of diabetes

University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.

14 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

Study finds new evidence that vitamin D decreases risk of autism in children

A study just published online in the peer-reviewed journal Dermato-Endocrinology found additional evidence that vitamin D reduces the risk of developing autism.

14 Dec 2012

Administration of N2O + ISO appears to have negative effect on fetal development

An anesthetic regimen typically used during surgery on pregnant mothers appears to have a negative effect on the development of the fetus, according to a new study on mice conducted by neurobiologists from the National Center for Toxicological Research, in Arizona.

14 Dec 2012

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

More than two-thirds of generic drugs have incomplete or incorrect safety-warning labels

Despite U.S. Food and Drug Administration regulations requiring generic medications to carry identical warnings to those on corresponding brand-name products, a study by Regenstrief Institute researchers has found that more than two-thirds of generic drugs have safety-warning labels that differ from the equivalent brand-name drug.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Fatal imbalance between global disease burden and drug development

Despite important progress in research and development (R&D) for global health over the past decade, only a small fraction of new medicines developed between 2000 and 2011 were for the treatment of neglected diseases, highlighting the 'fatal imbalance' between global disease burden and drug development for some of the world most devastating illnesses, said Doctors Without Borders/M-decins Sans Fronti-res (MSF) and the Drugs for Neglected Diseases initiative (DNDi), in an analysis to be presented today at an international conference aimed at spurring medical innovations for these diseases.

13 Dec 2012

Scientists identify new antibiotic substances in Russian Brown frog's skin

Following up on an ancient Russian way of keeping milk from going sour - by putting a frog in the bucket of milk - scientists have identified a wealth of new antibiotic substances in the skin of the Russian Brown frog. The study appears in ACS' Journal of Proteome Research.

13 Dec 2012

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

13 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

Pharmaceutical News

Everolimus therapy might treat Myc-driven lymphoma

Novartis receives FDA approval for Signifor injection to treat Cushing's disease

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Study suggests that existing HIV drug could be a potential therapy for Staph infections

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Paroxetine could treat vascular complications of diabetes

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Study finds new evidence that vitamin D decreases risk of autism in children

Administration of N2O + ISO appears to have negative effect on fetal development

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

More than two-thirds of generic drugs have incomplete or incorrect safety-warning labels

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Fatal imbalance between global disease burden and drug development

Scientists identify new antibiotic substances in Russian Brown frog's skin

Doctors should use different therapies when treating older and younger patients with CLL

New way to effectively make designer drugs that hit collections of protein targets simultaneously

Opioids already in the body can enhance malignant tendencies of human cancer cells

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News